Xilio Therapeutics, Inc. Xilio Therapeutics, Inc.

Xilio Therapeutics, Inc.

XLO

Rank in Stocks #17693
Xilio Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to... Xilio Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to crafting immunotherapies aimed at strengthening the immune systems of cancer patients. A key part of their pipeline is XTX101, a tumor-selective anti-CTLA-4 monoclonal antibody that is currently undergoing Phase 1/2 clinical trials for various solid tumors. The company also develops a range of cytokine programs, including XTX202 (a modified IL-2), XTX301 (an IL-12 product candidate), and XTX401 (an IL-15 product candidate). These cytokine therapies are ingeniously engineered with a protein domain that keeps them inactive until proteases specific to the tumor microenvironment (TME) cleave this mask, thereby initiating their therapeutic activity. Xilio Therapeutics, Inc. was founded in 2016 and is based in Waltham, Massachusetts.
Share Price
$8.07
Last synced: 2026-11-13
Market Cap
$158.88M
Change (1 day)
-2.06%
Change (1 year)
-20.41%
Country

Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this

Category

Healthcare
Operating Margin for Xilio Therapeutics, Inc. (XLO)
Operating Margin as of November 2026 TTM: -74.87%
According to Xilio Therapeutics, Inc.'s latest financial reports, its current operating margin (TTM) is -74.87%. At the end of 2025 the company had an operating margin of -95.92%.
Operating Margin history for Xilio Therapeutics, Inc. from 2019 to 2026
Operating Margin at the end of each year
Year Operating Margin Change
2026 (TTM) -74.87% -21.95%
2025 -95.92% -89.96%
2024 -954.95% 0.00%
2023 0.00% 0.00%
2022 0.00% 0.00%
2021 0.00% 0.00%
2020 0.00% 0.00%
2019 0.00% 0.00%
Operating Margin for similar companies or competitors
Company Operating Margin Operating Margin Difference Country
-195.39% -97.39%
US
33.87% -100.45%
US
-116.04% -98.45%
US
25.57% -100.34%
AU
31.23% -100.42%
BE
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.

Questions about Xilio Therapeutics, Inc.'s operating margin

What is Xilio Therapeutics, Inc.'s operating margin?

Xilio Therapeutics, Inc.'s operating margin is -74.87%, as of Nov 2026.

What was Xilio Therapeutics, Inc.'s operating margin in 2025?

In 2025, Xilio Therapeutics, Inc.'s operating margin was -95.92%, compared with -954.95% in 2024.

How has Xilio Therapeutics, Inc.'s operating margin changed since 2020?

From 2020 to 2025, Xilio Therapeutics, Inc.'s operating margin was highest in 2023 (0.00%) and lowest in 2024 (-954.95%).

How does Xilio Therapeutics, Inc.'s operating margin compare with similar companies?

Xilio Therapeutics, Inc.'s operating margin (-74.87%) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 33.87%.